DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today provided updated information from its multi-center Phase 2 clinical evaluation of Lymphoseek. The Phase 2 clinical study was conducted at five leading cancer centers in patients with either melanoma or breast cancer. A total of eighty patients were enrolled in the study. The primary objective of the study was to demonstrate that Lymphoseek accurately identified the lymph node in at least 90% of the evaluable patients. An overall lymph node identification rate of 95% was achieved in the study.
